CSIMarket
 
Painreform Ltd  (PRFX)
Other Ticker:  
 
 
Price: $0.5050 $-0.02 -3.846%
Day's High: $0.54 Week Perf: -7.34 %
Day's Low: $ 0.51 30 Day Perf: 2.85 %
Volume (M): 25 52 Wk High: $ 8.59
Volume (M$): $ 12 52 Wk Avg: $2.41
Open: $0.53 52 Wk Low: $0.43



 Market Capitalization (Millions $) 5
 Shares Outstanding (Millions) 11
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -9
 Cash Flow (TTM) (Millions $) -12
 Capital Exp. (TTM) (Millions $) 0

Painreform Ltd
Painreform Ltd is a biopharmaceutical company based in Israel. The company specializes in developing novel, non-opioid pain management treatments. They focus on utilizing their proprietary extended-release platform technology to create improved drug formulations for the treatment of acute and chronic pain. Painreform aims to provide effective and safer alternatives to traditional opioid-based pain medications, which can be addictive and have numerous side effects. They are actively engaged in clinical trials and collaborations with other pharmaceutical companies to advance their innovative pain management solutions.


   Company Address: 65 Yigal Alon St., Tel Aviv 6744316
   Company Phone Number:    Stock Exchange / Ticker: NASDAQ PRFX
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

PainReforms PRF-110 Shows Promise in Phase 3 Bunionectomy Trial and Head-to-Head Comparison

Published Wed, Jun 26 2024 12:01 PM UTC

PainReform, a pharmaceutical company specializing in pain management, has recently made significant progress in its Phase 3 clinical trials for PRF-110, a novel drug aimed at providing extended postoperative pain relief. This article will analyze three key developments: the completion of enrollment in the second part of the bunionectomy trial, the expected release of top-lin...

Stock Market Announcement

Navigating Uncertainty: PainReform Ltd's Path to Compliance and Resilience

Published Fri, May 31 2024 8:15 PM UTC

PainReform Ltd Announces Non-Compliance with Nasdaq Listing Requirements
PainReform Ltd, a clinical-stage specialty pharmaceutical company, recently received a letter from the Nasdaq Listing Qualifications indicating that the Company is not in compliance with the minimum bid price requirement for continued listing. The requirement, set forth in Listing Rule 5550(a)(2), m...

Management Announcement

PainReform CEO Ilan Hadar Discusses PRF-110's Potential in Combating the Opioid Epidemic

Published Wed, May 8 2024 12:30 PM UTC


Introduction
In a recent interview with Proactiveinvestors.com, PainReform Ltd.'s CEO, Ilan Hadar, shed light on the latest developments surrounding PRF-110 and its potential to address the concerning opioid epidemic. As a clinical-stage specialty pharmaceutical company, PainReform focuses on reformulating established therapeutics to provide safer and more effective...

Stock Market Announcement

PainReform Successfully Closes Public Offering, Raises Significant Funds for Clinical Development

Published Thu, Apr 18 2024 6:20 PM UTC



TEL AVIV, Israel - PainReform Ltd. (Nasdaq: PRFX), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, has recently announced the successful closing of its public offering. The company raised an aggregate of 5,000,000 ordinary shares and warrants at a combined public offering price of $0.80 per share. Addition...

Financing Agreement

PainReform Secures $4 Million in Public Offering, Fueling Growth in Pharmaceutical Innovation

Published Tue, Apr 16 2024 12:01 PM UTC

PainReform's Public Offering Signals Growth in Clinical-Stage Pharmaceutical Industry
In a recent announcement, PainReform Ltd. (Nasdaq: PRFX), a clinical-stage specialty pharmaceutical company, unveiled the pricing of its public offering, marking a significant milestone for the company's growth. The offering includes 5,000,000 of PainReform's ordinary shares (or ordinar...






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com